Skip to content
DraconiticResearch
Search Sources API
186,123 studies31 sourcesUpdated just now
Peer-reviewedLicence not statedEuropean Journal of Cancer

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study

15 more authors

Related

  1. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
    Elie Rassy, Cécile Dalban, Emeline Colomba +17
    Clinical Genitourinary CancerPeer-reviewedLicence not stated19 citedGeneral biologyHAL
  2. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
    Emilien Billon, Cécile Dalban, Stephane Oudard +17
    European Urology OncologyPeer-reviewedLicence not stated6 citedGeneral biologyHAL
  3. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Emeline Guiard, Florian Clatot, Caroline Even +5
    European Journal of CancerPeer-reviewedPublisher termsFull text20 citedGeneral biologyOncologyHAL
  4. Yersinia Enterocolitica Infection Mimicking Colon Carcinoma With Hepatic Metastases
    Ricarda Lamprecht‐Bailer, Sigrid Sauernheimer, Abbas Agaimy +1
    United European Gastroenterology JournalPeer-reviewedCC BY-NC-ND 4.0Full textGenetics & genomicsPMCEurope PMC
  5. Efficacy of sound therapy in chronic tinnitus patients with mild hearing loss: a multicentre, double-blind, placebo-controlled randomized clinical trial
    Philippe Fournier, Hung Thai-Van, Pierre Reynard +16
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textNeuroscienceCrossref
BibTeX
@article{velev2026efficacy,
  title = {{Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study}},
  author = {Maud Velev and Cécile Dalban and Christine Chevreau and Gwenaelle Gravis and Sylvie Negrier and Brigitte Laguerre and Marine Gross-Goupil and Sylvain Ladoire and Delphine Borchiellini and Lionnel Geoffrois and Florence Joly and Frank Priou and Philippe Barthelemy and Mathieu Laramas and Berangère Narciso and Antoine Thiery-Vuillemin and Jean-François Berdah and Victoria Ferrari and Quentin Dominique Thomas and Cécile Mione and Hubert Curcio and Stephane Oudard and Florence Tantot and Bernard Escudier and Sylvie Chabaud and Laurence Albiges and Constance Thibault},
  journal = {European Journal of Cancer},
  year = {2026},
  month = sep,
  doi = {10.1016/j.ejca.2022.12.028},
  url = {https://hal.science/hal-05744874v1},
}
RIS
TY  - JOUR
TI  - Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
AU  - Maud Velev
AU  - Cécile Dalban
AU  - Christine Chevreau
AU  - Gwenaelle Gravis
AU  - Sylvie Negrier
AU  - Brigitte Laguerre
AU  - Marine Gross-Goupil
AU  - Sylvain Ladoire
AU  - Delphine Borchiellini
AU  - Lionnel Geoffrois
AU  - Florence Joly
AU  - Frank Priou
AU  - Philippe Barthelemy
AU  - Mathieu Laramas
AU  - Berangère Narciso
AU  - Antoine Thiery-Vuillemin
AU  - Jean-François Berdah
AU  - Victoria Ferrari
AU  - Quentin Dominique Thomas
AU  - Cécile Mione
AU  - Hubert Curcio
AU  - Stephane Oudard
AU  - Florence Tantot
AU  - Bernard Escudier
AU  - Sylvie Chabaud
AU  - Laurence Albiges
AU  - Constance Thibault
PY  - 2026
DA  - 2026/09/10
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2022.12.028
UR  - https://hal.science/hal-05744874v1
SN  - 0959-8049
ER  -